Elemento Lab

Publications

Found 261 results
Filters: First Letter Of Last Name is G  [Clear All Filters]
2017
Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLeah B, A Van den Heuvel PJ, Lev A, Garnett MJ, McDermott U et al..  2017.  Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.. PLoS One. 12(8):e0180541.
Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O.  2017.  A Computational Approach for Identifying Synergistic Drug Combinations.. PLoS Comput Biol. 13(1):e1005308.
Benedicto I, Lehmann GL, Ginsberg M, Nolan DJ, Bareja R, Elemento O, Salfati Z, Alam NM, Prusky GT, Llanos P et al..  2017.  Concerted regulation of retinal pigment epithelium basement membrane and barrier function by angiocrine factors.. Nat Commun. 8:15374.
Lis R, Karrasch CC, Poulos MG, Kunar B, Redmond D, Duran JGBarcia, Badwe CR, Schachterle W, Ginsberg M, Xiang J et al..  2017.  Conversion of adult endothelium to immunocompetent haematopoietic stem cells.. Nature. 545(7655):439-445.
Jiang Y, Ortega-Molina A, Geng H, Ying H-Y, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X et al..  2017.  CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.. Cancer Discov. 7(1):38-53.
Jiang Y, Ortega-Molina A, Geng H, Ying H-Y, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X et al..  2017.  CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.. Cancer Discov. 7(1):38-53.
Du W, Goldstein R, Jiang Y, Aly O, Cerchietti L, Melnick A, Elemento O.  2017.  Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model.. Cancer Res. 77(8):1818-1830.
Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM et al..  2017.  Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.. Cancer Discov. 7(8):868-883.
Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM et al..  2017.  Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.. Cancer Discov. 7(8):868-883.
Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM et al..  2017.  Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.. Cancer Discov. 7(8):868-883.
Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM et al..  2017.  Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.. Cancer Discov. 7(8):868-883.
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.
Romanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, Chakravarty D, Soong D, Cotter KA, Petris G, Dhingra P et al..  2017.  Inherited determinants of early recurrent somatic mutations in prostate cancer.. Nat Commun. 8(1):48.
Romanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, Chakravarty D, Soong D, Cotter KA, Petris G, Dhingra P et al..  2017.  Inherited determinants of early recurrent somatic mutations in prostate cancer.. Nat Commun. 8(1):48.
Carty M, Zamparo L, Sahin M, González A, Pelossof R, Elemento O, Leslie CS.  2017.  An integrated model for detecting significant chromatin interactions from high-resolution Hi-C data.. Nat Commun. 8:15454.
Amengual JE, Prabhu SA, Lombardo M, Zullo K, Johannet PM, Gonzalez Y, Scotto L, Serrano XJirau, Wei Y, Duong J et al..  2017.  Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.. Clin Cancer Res. 23(12):3084-3096.
Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.
Liberti MV, Dai Z, Wardell SE, Baccile JA, Liu X, Gao X, Baldi R, Mehrmohamadi M, Johnson MO, Madhukar NS et al..  2017.  A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product.. Cell Metab. 26(4):648-659.e8.
Mauer J, Luo X, Blanjoie A, Jiao X, Grozhik AV, Patil DP, Linder B, Pickering BF, Vasseur J-J, Chen Q et al..  2017.  Reversible methylation of mA in the 5' cap controls mRNA stability.. Nature. 541(7637):371-375.
Mauer J, Luo X, Blanjoie A, Jiao X, Grozhik AV, Patil DP, Linder B, Pickering BF, Vasseur J-J, Chen Q et al..  2017.  Reversible methylation of mA in the 5' cap controls mRNA stability.. Nature. 541(7637):371-375.
Dave B, Gonzalez DD, Bin Liu Z-, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD et al..  2017.  Role of RPL39 in Metaplastic Breast Cancer.. J Natl Cancer Inst. 109(6)
Dave B, Gonzalez DD, Bin Liu Z-, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD et al..  2017.  Role of RPL39 in Metaplastic Breast Cancer.. J Natl Cancer Inst. 109(6)
Dave B, Gonzalez DD, Bin Liu Z-, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD et al..  2017.  Role of RPL39 in Metaplastic Breast Cancer.. J Natl Cancer Inst. 109(6)